Navigation Links
Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
Date:6/12/2008

Reports Full Assessment of Data from Positive Phase 2a Trial

WALTHAM, Mass., June 12 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that based on feedback from the Food and Drug Administration, the Company plans to initiate a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar disorder later this year. This will be a multi-center, parallel arm placebo-controlled, clinical trial in which approximately 150 patients with bipolar disorder will receive either RG2417 or a placebo twice a day for eight-weeks. This study is designed to assess the efficacy and safety of RG2417 on the symptom of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Gary S. Sachs, M.D., founder and director of the Bipolar Clinic and Research Program at the Massachusetts General Hospital and an Associate Professor of Psychiatry at the Harvard Medical School will be the Principal Investigator of this study.

Repligen previously reported positive initial results from a Phase 2a clinical trial of RG2417 in patients with bipolar disorder. We have now completed our assessment of the data and have found that patients with a history of more frequent symptoms demonstrated greater improvements when treated with RG2417 than patients without a history of frequent symptoms. For example, patients with more than 5 episodes of depression over their entire life (n=50) demonstrated greater improvements in their symptoms of depression compared to patients with 5 or fewer lifetime episodes of depression. From weeks 2-6 of treatment, the patients with more than 5 lifetime episodes of depression who received RG2417 had an average improvement on MADRS of 5.5 points over place
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
(Date:12/24/2014)... SAN DIEGO , Dec. 24, 2014 /PRNewswire/ ... the West, developing the proprietary Natural Killer (NK) ... announces that Dr. Patrick Soon-Shiong , NantWorks ... into a definitive agreement to purchase approximately $48 ... In connection with the investment, he will be ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
(Date:12/24/2014)... Today, Yunx.co.uk, a hot style dress supplier that ... occasion outfits, unveils 65 new bridesmaid dresses ... prices, up to 80% off. , Yunx.co.uk’s dresses are ... designs, gorgeous looks and delicate craftsmanship. These new bridesmaid ... to designing and offering high-quality women’s dresses with fast ...
(Date:12/24/2014)... -- The holidays can be a challenge for people who ... and drinks. "This is the season in which many ... Dr. David Dodick, chair of the American Migraine Foundation, said ... to think through food and beverage choices, to help reduce ... professor of neurology at the Mayo Clinic in Scottsdale, Ariz. ...
(Date:12/24/2014)... By Tara Haelle ... (HealthDay News) -- Teens are more likely to start ... of attention-deficit hyperactivity disorder (ADHD) or conduct disorder, ... to counsel families about the risk of substance use ... William Brinkman, research director at Cincinnati Pediatric Research Group, ...
(Date:12/24/2014)... 2014 The Healthy Home Company has a ... families. In-Vest USA is dedicated to supporting ... our first responders. Today, these two organizations have joined forces ... them with body armor through In-Vest’s USA’s Bless the Vest ... happened this past week in New York. , ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Verde Pointe Dental ... than ever. "Last years homemade Christmas sweater lit up, ... The 2014 winner is Tandy Wilson for the second ... sweater enthusiast," says Kirk Kimmerling DDS. "She took pictures of ... on the sweater." , "Every year I enjoy ...
Breaking Medicine News(10 mins):Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:The Healthy Home Company and In-Vest USA Team Up to Save the Lives of Law Enforcement 2Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2
... developed by an immunologist Dr Brendan O'Sullivan of Brisbane, for ... skyrocketing rates// of medicines that is available for diabetes in ... UQ's Centre for Immunology and Cancer Research (CICR) are developing ... in obesity -- a common precursor to diabetes, reports foodconsumer.org. ...
... a million lives owing to treatment costs that very many ... Asia and Africa seem to be at the receiving end. ... coming out with a facility that would enable mass production ... capacity to lower the costs of each dose by 25 ...
... Major Pharmaceutical Company Roche launched its anti-cancer drug `Tarceva' ... patients//, suffering from lung cancer. ,The Managing Director ... tablet taken once a day and has the potential ... patients with locally advanced or metastatic Non-Small Cell Lung ...
... that the ?6.2bn upgrade of the NHS IT system ... magazine said that the group of academics are questioning if ... saying that the plan was under a "constant review" and ... 30,000 GPs in England to almost 300 hospitals by 2012. ...
... methods it ahs been found that survival rates following ... when emergency medical// personnel used a new form of ... Center. ,Cardiocerebral Resuscitation, is how this new approach is ... procedures. , ,In the words of Michael J. ...
... at assuming the role of a doctor but pretty bad ... University// of Technology has revealed that nearly half of all ... almost always higher than it should be. ,Over medication ... of overmedication have risen from 12% in 1987 to 33 ...
Cached Medicine News:Health News:Type 2 Diabetes Could Be Tackled Using Curry Colouring and Fat Mix 2Health News:Paramedics save more lives following unconventional rules 2
Fiber optic illumination with XHL xenon halogen illumination. Large-diameter glass viewing window with 3X magnification, airtight window seal and swivelling viewing window....
Designed for instrumentation under magnification. Both lens and speculum can be swivelled. Open construction to allow access and examination under magnification and illumination....
Cost-effective otoscope with xenon halogen illumination. Polycarbonate molded head. Acrylic viewing window with 3X magnification. Nasal and spreadable specula avaliable....
Provides 30% more illumination, high light output for true tissue. Wide-angle viewing lens, sealed system for pneumatic otoscopy....
Medicine Products: